Forest Laboratories, Inc. - FRX - Financial Statement Analysis

All financial statement analysis reports for your requested company can be accessed below. The SIC # column is the SIC Code for the industry under which the current company is analyzed. When a report is purchased the SIC Code indicated is the industry that the company displayed will be compared against. If a different industry is desired for comparison, purchase of a separate industry analysis is suggested.

In addition to the ratio analysis reports, the latest business news headlines involving your company or industry sector are hyperlinked for your convenience along with the stock ticker for the company displayed.

Financial statement analysis updated: May 19, 2013

Forest Laboratories, Inc. - SIC # 2834

Ticker	Exchange	SIC #	Website	Latest Ticker
FRX	New York	2834	http://www.frx.com/	38.53 -0.17
Select one of the five (5) financial statement analysis reports below to view the ratio analysis report for your selected company: Publicly Traded Company Industry Ratios Publicly Traded Company VS. Industry Ratios Publicly Traded Company VS Publicly Traded Company Private Company VS Publicly Traded Company
Latest Headlines for Forest Laboratories, Inc. Forest to Present Aclidinium Bromide and Roflumilast Clinical Data at the American Thoracic Society (ATS) International Conference - May 17th, 2013 6:08 am Finny Kuruvilla, Portfolio Manager of the Eventide Gilead Fund, Interviews with The Wall Street Transcript: Investing in Health Care Innovation - May 16th, 2013 11:23 am Forest Laboratories, Inc. to Present Data from Cariprazine and Levomilnacipran Phase 3 Trials at American Psychiatric Association Annual Meeting - May 16th, 2013 6:00 am Forest Reaches New 52-Week High (FRX) - May 14th, 2013 9:59 am Forest-Trevena Ink Deal - May 14th, 2013 9:10 am Ironwood and Forest to Present Linaclotide Data at Digestive Disease Week® 2013 - May 14th, 2013 6:00 am Europe Eases Corporate Tax Dodge as Worker Burdens Rise - May 12th, 2013 10:01 pm Analyst Moves: MU, FRX, AES, CVC - May 10th, 2013 8:12 am Analysts' Actions: MU BSX CVC FRX - May 10th, 2013 6:45 am Trevena, Inc. and Forest Laboratories Announce a Collaborative Agreement For Development of TRV027 for the Treatment of Acute Heart Failure - May 9th, 2013 4:00 am Trevena Inc. and Forest Laboratories Announce a Collaborative Agreement for Development of TRV027 for the Treatment of Acute Heart Failure - May 9th, 2013 4:00 am Positive Data on Forest Combo Drug - May 7th, 2013 1:30 pm Analyst downgrades Ironwood Pharma on expenses - May 6th, 2013 11:47 am Analyst downgrades Ironwood Pharma on expenses - May 6th, 2013 11:47 am Take a Deep Breath Before This Big FDA Decision - May 5th, 2013 12:30 pm Icahn Enterprises 1Q net income surges - May 3rd, 2013 10:33 am Icahn Enterprises 1Q net income surges - May 3rd, 2013 10:33 am Mylan Reports in line Earnings - May 3rd, 2013 6:15 am Alternative Dosage Forms Create Barriers Against Competition in Generics: A Wall Street Transcript Interview with David Amsellem, Managing Director and Senior Research Analyst at Piper Jaffray & Co. - May 2nd, 2013 9:08 am 3 Healthcare Stock Stories For Midweek Wellness - May 2nd, 2013 6:34 am View All Current Headlines >>